Dr. Sajeve Samuel Thomas, MD

Dr. Thomas practices at AdventHealth Orlando in Orlando, Florida, part of AdventHealth.

Dr. Thomas' NPI, 1760677108, was assigned on September 10, 2007. Dr. Thomas graduated from University Of Florida College Of Medicine in 2005. Dr. Thomas holds Florida license ME100566.

Dr. Thomas' primary practice is AdventHealth Orlando, at 601 E Rollins St, Orlando, FL 32803 in Orange County. The practice phone is (407) 303-1976.

Dr. Thomas' primary practice is AdventHealth Orlando in Orlando, Florida, part of AdventHealth. Dr. Thomas is also affiliated with Charleston Area Medical Center General Hospital. The medical group on file is AdventHealth Medical Group. Dmand AI also links Dr. Thomas to 3 more hospitals, 2 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Thomas practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Thomas' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Thomas is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Thomas' licenses on file in 3 states: Florida, Montana and West Virginia.

Dmand AI lists chronic leukemia, colorectal cancer, lung cancer and prostate cancer among the conditions Dr. Thomas treats.

CMS data shows 490 Medicare services from Dr. Thomas across 6 procedure codes in 2024, for 251 Medicare patients. Medicare paid $48,195 for them.

CMS counts 251 Medicare patients who saw Dr. Thomas in 2024. The largest group is 65 to 74, with 105 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 11% are also on Medicaid. Their average risk score is 2.26, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Thomas' median patient age at 70, with 47% women.

In 2024, Dr. Thomas wrote 591 Medicare Part D claims for 112 patients. 63% of them were for generic drugs. CMS names the drug for 370 of them, across 16 drugs with 11 or more claims each, at $1,340,868 in total drug cost. In 2023, CMS named 540 claims across 21 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 99 out of 100 for Dr. Thomas for performance year 2024, reported through an alternative payment model (APM). Dr. Thomas accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Thomas as offering telehealth.

Dmand AI links 13 papers to Dr. Thomas, published from 2011 to 2025. 2024 was the busiest year, with 2. The most frequent topics are Melanoma, Antibodies, Monoclonal, Humanized and Antineoplastic Combined Chemotherapy Protocols. Dr. Thomas has published most often in J Clin Oncol. Dr. Thomas' most frequent co-authors are Omid Hamid, MD, Theresa Michelle Medina, MD and Harriet Margot Kluger, MD.

Dmand AI links Dr. Thomas to 14 clinical trials, 6 of them phase 3 studies. 7 are still active or recruiting. Conditions studied include Melanoma, Nevi and Melanomas and Rectal Diseases. National Cancer Institute (NCI) sponsors the most, 7. Open Payments lists research payments to Dr. Thomas that name 4 trials.

CMS Open Payments shows 1,024 general payments to Dr. Thomas from 30 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 68% of the total. Bristol-Myers Squibb Company paid the most, $556,438. It also lists 49 research payments totaling $12,294 from 2022 to 2025, naming 4 clinical trials.

Dr. Thomas graduated from University Of Florida College Of Medicine in 2005.

Dr. Thomas is in network with 15 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.